ALTERNATE SYNTHESIS OF APIXABAN (BMS-562247), AN INHIBITOR OF BLOOD COAGULATION FACTOR XA

被引：27

作者：

Jiang, Jian'an ^{[1
]}

Ji, Yafei ^{[1
]}

机构：

[1] E China Univ Sci & Technol, Sch Pharm, Shanghai 200237, Peoples R China

来源：

SYNTHETIC COMMUNICATIONS | 2013年 / 43卷 / 01期

关键词：

Apixaban; cost-effective synthetic route; inhibitor of blood coagulation factor Xa; 4-nitroaniline; THROMBOSIS;

D O I：

10.1080/00397911.2011.591956

中图分类号：

O62 [有机化学];

学科分类号：

070303 ; 081704 ;

摘要：

An alternate approach to apixaban was described. The synthesis features a novel and cost-effective synthetic strategy to construct a key N-phenylvalerolactam intermediate 4 from 4-nitroaniline. In addition, the modified synthetic route avoids the use of expensive reagents and significantly improves reaction yields. As demonstrated practically, apixaban was successfully synthesized in overall good yield (35%).

引用

页码：72 / 79

页数：8

共 13 条

[1] VINYLOGOUS CARBINOLAMINE TUMOR INHIBITORS .13. SYNTHESIS AND EVALUATION OF FURAN, THIOPHENE, AND AZOLE BIS[(CARBAMOYLOXY)METHYL] DERIVATIVES AS POTENTIAL ANTINEOPLASTIC AGENTS
ANDERSON, WK
JONES, AN
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 1984, 27 (12) : 1559 - 1565
[2] Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome
Becker, Richard C.
Alexander, John H.
Newby, L. Kristin
Yang, Hongqiu
Barrett, Yuchen
Mohan, Puneet
Wang, Jessie
Harrington, Robert A.
Wallentin, Lars C.
[J]. THROMBOSIS AND HAEMOSTASIS, 2010, 104 (05) : 976 - 983
[3] 1,3-Dipolar Cycloaddition of Nitrile Imines with Functionalized Acetylenes: Regiocontrolled Sc(OTf)3-Catalyzed Synthesis of 4-and 5-Substituted Pyrazoles
Bonini, Bianca Flavia
Franchini, Mauro Comes
Gentili, Denis
Locatelli, Erika
Ricci, Alfredo
[J]. SYNLETT, 2009, (14) : 2328 - 2332
[4] Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study
Buller, H.
Deitchman, D.
Prins, M.
Segers, A.
[J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2008, 6 (08) : 1313 - 1318
[5] Gant T. G., 2010, [No title captured], Patent No. [WO 2010030983 A2, 2010030983]
[6] Molecular Design of Pyrazolo[3,4-d]pyridazines
Matiichuk, V. S.
Potopnyk, M. A.
Obushak, N. D.
[J]. RUSSIAN JOURNAL OF ORGANIC CHEMISTRY, 2008, 44 (09) : 1352 - 1361
[7] Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa
Pinto, Donald J. P.
Orwat, Michael J.
Koch, Stephanie
Rossi, Karen A.
Alexander, Richard S.
Smallwood, Angela
Wong, Pancras C.
Rendina, Alan R.
Luettgen, Joseph M.
Knabb, Robert M.
He, Kan
Xin, Baomin
Wexler, Ruth R.
Lam, Patrick Y. S.
[J]. JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (22) : 5339 - 5356
[8] Synthesis and characterization of a new trans-2,2′-azoquinoxaline bridged bisphthalocyanine
Salan, Ü
Altindal, A
Bulut, M
Bekaroglu, Ö
[J]. TETRAHEDRON LETTERS, 2005, 46 (36) : 6057 - 6061
[9] Effect of the Direct Factor Xa Inhibitor Apixaban in Rat Models of Thrombosis and Hemostasis
Schumacher, William A.
Bostwick, Jeffrey S.
Stewart, Anne B.
Steinbacher, Thomas E.
Xin, Baomin
Wong, Pancras C.
[J]. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2010, 55 (06) : 609 - 616
[10] Oral, direct Factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases
Turpie, Alexander G. G.
[J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2007, 27 (06) : 1238 - 1247

← 1 2 →